Article in Lung, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 1 institution in 1 country.
Justin K LuiThe Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, R‑304, Boston, MA, 02118, USA. justin.lui@bmc.org.ORCID 0000-0002-4745-3766
Kari R GillmeyerThe Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, R‑304, Boston, MA, 02118, USA.ORCID 0000-0002-5333-259X
Ruchika A SanganiThe Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, R‑304, Boston, MA, 02118, USA.ORCID 0000-0003-1982-4408
Robert J SmythThe Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, R‑304, Boston, MA, 02118, USA.ORCID 0000-0001-7613-9306
Deepa M GopalSection of Cardiovascular Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0003-3534-9360
Marcin A TrojanowskiSection of Rheumatology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0003-2583-1591
Andreea M BujorSection of Rheumatology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-8840-8937
Renda Soylemez WienerThe Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, R‑304, Boston, MA, 02118, USA.ORCID 0000-0001-7712-2135
Michael P LaValleySection of Rheumatology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-8488-5170
Elizabeth S KlingsThe Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, R‑304, Boston, MA, 02118, USA.ORCID 0000-0003-4879-720X
Boston University · US
Funding
Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Research and Evaluation Support Core Unit (RESCU Core)P30AR072571 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Michael Paul Lavalley · 2019 to 2026
$6.9M
The role of Fli1 in myeloid cells and its contribution to cardiac fibrosisR01HL155955 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BUJOR, ANDREEA MONICA · 2021 to 2025
$2.1M
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)UG3HL143192 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GLADWIN, MARK T, TRIULZI, DARRELL J · 2019 to 2019
We devised a scoring system to identify patients with systemic sclerosis (SSc) at risk for pulmonary hypertension (PH) and predict all-cause mortality. Using 7 variables obtained via pulmonary function testing, echocardiography, and computed tomographic chest imaging, we applied the score to a retrospective cohort of 117 patients with SSc. There were 60 (51.3%) who were diagnosed with PH by right heart catheterization. Using a scoring threshold ≥ 0, our decision tool predicted PH with a sensitivity, specificity, and accuracy of 0.87 (95% CI 0.75, 0.94), 0.74 (95% CI 0.60, 0.84), and 0.80 (95% CI 0.72, 0.87), respectively. When adjusted for age at PH diagnosis, sex, and receipt of pulmonary arterial vasodilators, each one-point score increase was associated with an adjusted HR of 1.19 (95% CI 1.05, 1.34) for all-cause mortality. With further validation in external cohorts, our simplified clinical decision tool may better streamline earlier detection of PH in SSc.
Indexed as
Hypertension, PulmonaryScleroderma, SystemicCardiac CatheterizationEchocardiographyHumansRetrospective StudiesClinical prediction ruleConnective tissue diseaseDiffuse sclerodermaLimited sclerodermaPulmonary arteryPulmonary function test
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension. · full record | OpenQuestion